Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: Report of two cases of disappearance of viral replication after acute hepatitis

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 973-977

  Peyrière, Hélène ^a   Tatem, Ludmilla ^a   Bories, Camille ^b   Pageaux, Georges Philippe ^b   Blayac, Jean Pierre ^a   Larrey, Dominique ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Acute hepatitis; Buprenorphine; Hepatitis C; Injection; Misuse

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; BUPRENORPHINE; VIRUS RNA;

ADULT; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; ENZYME BLOOD LEVEL; HELPER VIRUS; HEPATITIS C; HEROIN DEPENDENCE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; JAUNDICE; LABORATORY TEST; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS REPLICATION;

ACUTE DISEASE; ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; CARRIER STATE; HEPACIVIRUS; HEPATITIS C; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; VIRUS REPLICATION;

EID: 65749112937     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L628     Document Type: Article

References (26)

1. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-110. (Pubitemid 11144150)
2. Product information. Buprenorphine (Subutex) sublingual oral tablets. Richmond, VA: Reckitt Benckiser Pharmaceuticals, Inc., June 2005.
3. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346-350 (Pubitemid 32176462)
4. Houdret N, Asnar V, Szostak-Talbodec N, et al. Hepatonephritis and massive ingestion of buprenorphine. Acta Clin Belg 1999;1(suppl 1):29-31.
5. Herve S, Riachi G, Noblet C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004;16:1033-1037
6. Zuin M, Giorgini A, Selmi C, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2008 Feb 20 [Epub ahead of print].
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
8. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330
9. Lucena MI, Camargo R, Andrade RJ, Pérez-Sanchez CJ, Sánchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-130 (Pubitemid 32016894)
10. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-181 (Pubitemid 36262027)
11. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008;97:105-113
12. Berson A, Fau D, Fornacciari R, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001;34:261-269
13. Brewster D, Humphrey MJ, Mcleavy MA. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol 1981;33:500-506 (Pubitemid 11022008)
14. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clincal pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-580 (Pubitemid 24192243)
15. Piccoli C, Scrima R, D'Aprile A, et al. Mitochondrial dysfunction in hepatitis C virus infection. Biochim Biophys Acta 2006;1757:1429-1437
16. Mansouri A, Gaou I, De Kerguenec C, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 1999;117:181-190
17. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C, Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991;259:894-904.
18. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol 2003;38(suppl 1):S104-18. (Pubitemid 36286566)
19. Scott JD, McMahon BJ, Bruden D, et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska natives. Clin Infect Dis 2006;42:945-952
20. Byrnes B, Chopra S, Koziel MJ. Resolution of chronic hepatitis C following parasitosis. World J Gastroenterol 2007;13:4268-4269 (Pubitemid 47377169)
21. Gruener NH, Jung MC, Ulsenheimer A, et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol 2002;37:866-889
22. Somsouk M, Lauer GM, Casson D, et al. Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology 2003;124:1946-1949.
23. Koziel MJ. Cellular immune responses against hepatitis C virus. Clin Infect Dis 2005;41(suppl 1):S25-31.
24. Brunelle E, Ledru S, Rotily M, et al Spontaneous clearance of hepatitis C virus after long-term opiate dependence therapy with buprenorphine. J Viral Hepat 2004;11:571-573 (Pubitemid 39486622)
25. Li Y, Zhang T, Douglas SD, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003;163:1167-1175
26. Yokosuka O, Kojima H, Imazeki F, et al. Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 1999;31:394-399